Omeros - Crunchbase Company Profile & Funding

Q: Where is Omeros's headquarters?

Omeros is located in Seattle, Washington, United States.

Q: Who invested in Omeros?

Omeros has 20 investors including Polar Asset Management Partners And National Institute on Drug Abuse (NIDA).

Q: When was the last funding round for Omeros?

Omeros closed its last funding round on obfuscated from a Post-IPO Equity round.

Overview

Omeros

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Omeros

CB Rank

28483

Omeros is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.

Founded

obfuscation

Public

Post-IPO Equity

Seattle, Washington, United States

101-250

www.omeros.com

Biotechnology

Health Care

Pharmaceutical

Funding Rounds

Post-IPO Equity

OBF

obfuscation

Post-IPO Debt

OBF

obfuscation

Grant

OBF

obfuscation

Key People

Gregory Demopulos: President, CEO, Chairman and founder
Timothy Duffy: Vice President, Business Development
Past Role: Pacific Crest Ventures, Managing Director

Details

Legal Name

Omeros Corporation

Operating Status

Active

Stock Symbol

NASDAQ:OMER

Company Type

For Profit

Founders

Gregory Demopulos, Pamela Pierce Palmer

About the Company

Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.

Phone Number

2066765005

Diversity Spotlight

Women Founded

Predictions & Insights

Growth Insight

See this Growth Insight

Omeros is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Products & Services

Narsoplimab (OMS721)

A monoclonal antibody targeting MASP-2 to inhibit the lectin pathway of the complement system, used to treat complement-mediated diseases like stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

OMS906 (Zaltenibart)

A humanized monoclonal antibody targeting MASP-3 to inhibit the alternative pathway of the complement system, under development for diseases like paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy.

Research & Development

Omeros is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Omeros	1	obfuscated obfuscation	Polar Asset Management Partners	Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Polar Asset Management Partners	Yes	Post-IPO Equity - Omeros	—
Polar Asset Management Partners	Yes	Post-IPO Equity - Omeros	—
Polar Asset Management Partners	Yes	Post-IPO Equity - Omeros	—
Polar Asset Management Partners	Yes	Post-IPO Equity - Omeros	—
Polar Asset Management Partners	Yes	Post-IPO Equity - Omeros	—